Table 2 Clinical trials and an approved therapy based on AS-ON technologies [31-33].
Product | Company | Target | Disease | Chemistry | Status |
|---|---|---|---|---|---|
Vitravene (Fomivirsen) | ISIS Pharmaceuticals | CMV IE2 | CMV retinitis | PS DNA | Approved in 1998 |
Affinitac (ISIS 3521) | ISIS | PKC-α | Cancer | PS DNA | Phase III |
Genasense | Genta | Bcl2 | Cancer | PS DNA | Phase III |
Alicaforsen (ISIS 2302) | ISIS | ICAM-1 | Psoriasis, Crohn's disease, Ulcerative colitis | PS DNA | Phase II/III |
ISIS 14803 | ISIS | Antiviral | Hepatitis C | PS DNA | Phase II |
ISIS 2503 | ISIS | H-ras | Cancer | PS DNA | Phase II |
MG98 | Methylgene | DNA methyl transferase | Solid tumors | PS DNA | Phase II |
EPI-2010 | EpiGenesis Pharmaceuticals | Adenosine A1 receptor | Asthma | PS DNA | Phase II |
GTI 2040 | Lorus Therapeutics | Ribonucleotide reductase (R2) | Cancer | PS DNA | Phase II |
ISIS 104838 | ISIS | TNFα | Rheumatoid Arthritis, Psoriasis | 2nd generation | Phase II |
Avi4126 | AVI BioPharma | c-myc | Restenosis, cancer, Polycystic kidney disease | 3rd generation | Phase I/II |
Gem231 | Hybridon | PKA RIα | Solid tumors | 2nd generation | Phase I/II |
Gem92 | Hybridon | HIV gag | AIDS | 2nd generation | Phase I |
GTI 2051 | Lorus Therapeutics | Ribonucleotide reductase (R1) | Cancer | PS DNA | Phase I |
Avi4557 | AVI BioPharma | CYP3A4 | Metabolic redirection of approved drugs | 3rd generation | Phase I |